Experimental Breast Cancer Drug

Patients with advanced disease lived twice as long.
An experimental drug shows promising results in treating advanced breast cancer. Researchers say in a study of 165 patients, the drug palbociclib, stopped tumors from growing a little more than 20 months. That's twice as long as the current treatment.

Patients who took palbociclib also took lived longer, but not by a significant amount. Those who received the drug lived about 37.5 months, compared with 33.3 months for those in the control group.

The drug is intended for patients with hormone receptor-positive, metastatic breast cancer.
Page: [[$index + 1]]
comments powered by Disqus